Oligo Factory Announces GMP Compliance

Jan 03, 2024

HOLLISTON, Mass.–Oligo Factory, a leading manufacturer of high-quality oligonucleotides at scale, announces today that it is compliant with current Good Manufacturing Practices (GMP). This milestone emphasizes Oligo Factory’s commitment to exceptional quality control, adherence to stringent global regulatory standards, and customer service.

GMP ICHQ7 compliance is a critical benchmark for the pharmaceutical and biotechnology industries, ensuring that products are produced consistently and abide by the highest quality standards. Oligo Factory has implemented a comprehensive quality management system to align its operations with GMP guidelines. This includes enhanced documentation and traceability practices, rigorous training programs for employees, regular audits, and continuous improvement initiatives. By integrating these measures into its manufacturing process, Oligo Factory can now serve its customer base more fully and enhance the level of quality and consistency across its oligonucleotide products.

“We are thrilled to announce our GMP ICHQ7 compliance. I’m extremely proud of our team who worked tirelessly throughout 2023 to achieve this milestone,” said Chris Boggess, CEO of Oligo Factory. “This accomplishment reflects our unwavering commitment to producing oligonucleotides of the highest quality to meet the growing demand from our valued customers in the pharmaceutical and biotech industries.”

Oligo Factory’s GMP-compliant products support a range of applications, including drug discovery, therapeutic development, diagnostic testing, and more. In early 2023, Oligo Factory opened a state-of-the-art oligonucleotide synthesis facility in Holliston, MA, to meet growing demand for its services. The new facility, with over 13,000 sq ft of laboratory and office space, increases oligo synthesis capacity by 12x and purification and lyophilization by 10x.

Download Attachment

See all Member News